1. Introduction {#sec1}
===============

MicroRNAs (miRNAs), endogenous noncoding single‐stranded RNAs with 20-25 nucleotides in length, regulate gene expression by binding with imperfect complementarity to the 3late gene expression at specific mRNAs. They may regulate approximately 60% genes in human protein-coding \[[@B1], [@B2]\]. Previous studies have demonstrated that miRNAs play important roles in various fundamental and biological processes including cell differentiation, proliferation, metabolism, differentiation, and apoptosis \[[@B3], [@B4]\]. It is well documented that some miRNAs act as tumor suppressors or oncogenes, which is frequently down-/upregulated in malignancies. \[[@B5]\] Because of their non-invasive as well as unique expression patterns, miRNAs were accepted as good diagnostic or prognostic biomarker in human cancer research.

MiRNA-15a is an important part of the miRNA-15 family \[[@B6]\], which has been reported to function as a tumor suppressor in carcinogenesis via targeting oncogenes. For example, anti-apoptotic BCL2 in chronic lymphocytic leukemia (CLL) and other cancers \[[@B7]\] and BMI1 in gastric cancer as well as pancreatic cancer act as a stem cell marker and promoter of migration and invasion \[[@B8]\]. MiRNA-15a also targets MCL1, WNT3A, and MCL1 \[[@B9]\]. Downregulation of miRNA-15a has recently been reported in patients with CLL \[[@B7]\], non-small-cell lung cancer \[[@B10]\], prostate cancer \[[@B11]\], ovarian cancer \[[@B12]\], and hepatocellular carcinoma \[[@B13]\]. As an important member of miRNA-15/16 cluster, the influence of miRNA-15a on the prognosis of colorectal cancer \[[@B14]--[@B17]\], osteosarcoma \[[@B18]\], esophageal squamous cell carcinoma \[[@B19]\], glioma \[[@B20]\], breast cancer \[[@B21]\], cholangiocarcinoma \[[@B22]\], and multiple myeloma \[[@B23]\] has been reported. However, the results were insignificant or opposite. Thus, we conducted this meta-analysis to comprehensively assess the prognostic value of miRNA-15a expression level in human cancers.

2. Materials and Methods {#sec2}
========================

2.1. Search Strategy {#sec2.1}
--------------------

The meta-analysis according to the guidelines of the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) statement and methods. \[[@B24]\] We retrieved some online databases consisting of PubMed, Embase, and Web of Science to find eligible studies till October 2018. The articles were searched by using the following keywords: microRNA-15a, miRNA-15a, and miR-15a combined with prognosis, prognostic or survival. We use the following aspects to identify if the literature is duplicated, including author names, institutions, clinical trial registration number, numbers of participants, baseline data, and specific details of the interventions. For the literature that has been reported many times by the same author, we select the latest and most complete inclusion. Additionally, we manually searched previous reviews and the references list to the literature included in our study to find out additional relevant studies. [Figure 1](#fig1){ref-type="fig"} showed the flow diagram of the literature selection process.

2.2. Data Extraction {#sec2.2}
--------------------

Each study was revised by two reviewers (FRY and TTL) followed a standard data extraction form. Discrepancies were solved by fully discussing with HJL or further reviewed by XRL. Eligible studies must comply with the following criteria: (1) study about the correlation of miRNA-15a with any type of cancer prognosis; (2) publication details: disease name, publication year, and first author\'s last name; (3) the effect size being evaluated using multivariate HRs with 95% confidence intervals (CI) for OS or DFS, if the HRs cannot be obtained directly from the original studies, data were calculated by Kaplan-Meier curves according to the method provided by Tierney et al. \[[@B25]\] Studies were excluded if one of the following criteria was met: (1) review, case report, abstracts, or letters to editor; (2) duplicate articles; (3) animal models or cell lines as research subject; (4) survival data lacking or being unable to calculate them.

2.3. Quality Assessment {#sec2.3}
-----------------------

All the enrolled literature was evaluated by Newcastle-Ottawa scale. This quality evaluation scale of literature contains the following three aspects: study groups selection, comparison of study groups, and measuring of outcomes. The score of this scale is ranged from 0 to 9.

2.4. Bioinformatics Analysis {#sec2.4}
----------------------------

To further validate and complement this meta-analysis, we used the Kaplan-Meier plotter database and miRpower for pan-cancer tool to analyze the relationship between miRNA-15a expression and OS of human cancers (<http://kmplot.com/analysis/index.php?p=service&cancer=pancancer_mirna>). \[[@B26]\] If the*P*-value is less than 0.05, it is considered statistically significant.

2.5. Statistical Analysis {#sec2.5}
-------------------------

The pooled HRs were calculated by HRs with 95% CIs. Heterogeneity between pooled studies was evaluated by Cochran\'s Q test and Higgin\'s*I*^2^ statistic. We preferred to use fixed-model if there is no significant heterogeneity (P\>0.1 and*I*^*2*^*\<50%)*; otherwise, we used the random-effect model. Publication bias was evaluated using the funnel plot with Begg\'s statistical test. We use the STATA software for statistical analysis (STATA Corporation, College Station, USA, version 14.0).

3. Results {#sec3}
==========

3.1. Features of Studying {#sec3.1}
-------------------------

We used the search strategy provided above to retrieve 488 records from online databases. By manually reviewing titles and abstracts, we rejected duplicates and unavailable literature. Then 82 articles were selected for full-text browsing. Finally, ten studies were included and there was no additional article by consulting the cross-references. Ten studies consisted of 1616 samples from China, US, Australia, Greece, Japan, and Thailand and were included to evaluate the relationship between miRNA-15a expression and cancer prognosis. Eight of the 10 studies detected the expression of miRNA-15a in tumor tissue and another two studies \[[@B19], [@B23]\] detected in serum and bone marrow, respectively. To measure the expression of miRNA-15a, all of the studies used qRT-PCR. Six of 10 studies used the exact value of miRNA expression as the cut-off value, two studies used the median value \[[@B17], [@B20]\], and the remaining two studies did not provide relevant information. \[[@B21], [@B22]\] For survival assessment criteria, all incorporated literature used OS and five studies used DFS. \[[@B16], [@B17], [@B19]--[@B21]\] The HRs and 95% CIs were directly acquired in seven studies, evaluation from the survival curve in three records. \[[@B14], [@B15], [@B19]\] The main features of the available studies have been listed in [Table 1](#tab1){ref-type="table"}. Summary of HRs and their 95% CI are shown in [Table 2](#tab2){ref-type="table"}.

3.2. Qualitative Assessment {#sec3.2}
---------------------------

After using Newcastle--Ottawa scale to assess the quality of studies, the study quality score \>6 was included. The main characteristics of the eligible studies are summarized in [Table 3](#tab3){ref-type="table"}.

3.3. Meta-Analysis Results {#sec3.3}
--------------------------

All the studies with 1616 cancer patients we have included were involved in OS analysis. Because of high heterogeneity (*I*^2^ =66.6%, P=0.001), we chose a random-effect model to compare between low expression of miRNA-15a and high expression. The result showed that lower expression of miRNA-15a indicating adverse OS (HR=2.17, 95% CI: 1.41-3.34; [Figure 2(a)](#fig2){ref-type="fig"}), and the results are statistically significant (P\<0.001). Five studies with 772 cancer patients were involved in DFS analysis; a pooled HRs and its 95% CIs were conducted with random-effect model due to the high heterogeneity (*I*^2^ =90.4%, P=0.001). We found that there is no significant association between the expressing level and DFS in cancer patients (HR=2.04, 95% CI: 0.60-6.88; [Figure 2(b)](#fig2){ref-type="fig"}.

In this study, we performed a subgroup analysis based on the main characteristics of the included studies. The results indicated that the prognosis value of miRNA-15a was significant in tissue specimen (HR=1.97, 95% CI: 1.22-3.19), serum or bone marrow specimen (HR=3.63, 95% CI: 1.70-7.76), and Asia patients (HR=3.10, 95% CI: 2.21-4.34). The association between downregulation of micro-RNA15a expression and shorter OS time was not obvious in the subgroup of European and colorectal cancer patients. ([Table 4](#tab4){ref-type="table"})

3.4. Survival Analysis of Human Cancers through the Kaplan--Meier Plotter Database {#sec3.4}
----------------------------------------------------------------------------------

Survival analysis was performed through the Kaplan--Meier plotter database to validation for the results of meta-analysis which included 7385 patients with various types of cancer ([Table 5](#tab5){ref-type="table"}). The results showed that although the probability of death in the low-expression group was 1.165 times higher than that in the high-expression group, there was no statistical difference (HR=1.165, 95%CI 0.95-1.44;*P*=0.150). However, in the survival analysis of a single cancer types, we found that low-expression miRNA-15a was significantly associated with worse OS in bladder Carcinoma (HR=1.49, 95%CI 1.11-2.00;*P*=0.0081), head-neck squamous cell carcinoma (HR=1.43, 95%CI 1.04-1.96;*P*=0.027), liver hepatocellular carcinoma (HR=1.54, 95%CI 1.08-2.22;*P*=0.017), lung squamous cell carcinoma (HR=1.69, 95%CI 1.22-2.38;*P*=0.0014), pancreatic ductal adenocarcinoma (HR=2.22, 95%CI 1.43-3.45;*P*=0.0002), rectum adenocarcinoma (HR=2.63, 95%CI 1.19-5.88;*P*=0.013), stomach adenocarcinoma (HR=1.52, 95%CI 1.10-2.08;*P*=0.011), and uterine corpus endometrial carcinoma (HR=1.69, 95%CI 1.10-2.63;*P*=0.015), whereas the results were opposite in cervical squamous cell carcinoma (HR=0.55, 95%CI 0.32-0.93;*P*=0.026) and esophageal carcinoma (HR=0.53, 95%CI 0.34-0.85;*P*=0.0072) ([Figure 3](#fig3){ref-type="fig"}). In the other caner types, there is no significant association between the expression of miRNA-15a and human cancers. Thus, most of the results from Kaplan--Meier plotter database were consistent with our meta-analysis.

3.5. Sensitivity Analysis {#sec3.5}
-------------------------

To assess the stability of the meta-analysis results, we carried out sensitivity analysis by excluding studies one by one. After each study is excluded, the pooled HR was recalculated. The result showed that the stability of the entire study was not affected by a certain study ([Figure 4](#fig4){ref-type="fig"}).

3.6. Publication Bias Assessment {#sec3.6}
--------------------------------

Publication bias for the OS meta-analysis among included studies was evaluated by Bgger\'s funnel plot ([Figure 5](#fig5){ref-type="fig"}). The funnel plot was basically symmetrical and the P-value of Bgger\'s regression intercepts was 0.107. Consequently, there was no significant risk of publication bias in this meta-analysis.

4. Discussion {#sec4}
=============

As a class of tiny regulatory RNA molecules, miRNA plays an important role in gene expression and diverse biological processes. They can blind to the 3′UTR and 5′UTR of their target mRNAs. A large number of studies have demonstrated that tumor invasion and metastasis are regulated by miRNAs, and they are used to analyze the prognosis of a variety of tumors. For example, Wang et al. have demonstrated that overexpression of miRNA-34a significantly predicted good OS in cancer patients. \[[@B27]\] Zhang et al. found that downregulated miRNA-183 was notably indicated for poor OS. \[[@B28]\] Hence, miRNAs have the potential to be used as a biomarker for analyzing tumor prognosis.

MiRNA-15a was the first miRNA to be discovered as a tumor suppressor in CLL. \[[@B29]\] MiRNA-15a belongs to the miRNA-15 family, which is located on chromosome 13 (13q14) and consists of miRNA-15a/b, miRNA-16-1, miRNA-16-2, miRNA-497, and miRNA-195. \[[@B6]\] Furthermore, they are located in the intron of DLEU2, which is a long non-coding RNA (lncRNA) gene. \[[@B30]\] Plenty of researches have revealed that the expression level of miRNA-15a is adjusted by many factors, such as transcription factors and epigenetic and chromosomal deletions. Cutrona et al. discovered that the chromosome 13q14 deletion is related to a significant downregulation of miRNA-15a and the pathogenesis of CLL. \[[@B31]\] The mechanism by which miRNA-15a promotes tumor progression remains complex; therefore, more researches are needed to disclose it. Some researches have discovered that miRNA-15a inhibits cell proliferation by modulating many specific targets. For example, cyclin has been revealed to play critical roles in cell proliferation. In CLL, breast cancer, and lung cancer, DLEU2 downregulates cyclins by upregulating miRNA-15a, leading to cell cycle arrest in the G1 to G0 phase. \[[@B32], [@B33]\] Related studies have shown that the pathogenesis of many cancers is closely related to the abnormal regulation of apoptosis. Bcl-2 has been shown as a critical gene in cell apoptosis and it is a significant target of miRNA-15a in CLL. Deletion of 13q14 resulted in downregulation of miRNA-15a and overexpression of Bcl-2. \[[@B34]\] As we know, EMT (epithelial--mesenchymal transition) is an important biological process for malignant tumor cells to acquire the ability of migration and invasion, and Twist1 as a transcription factor plays a decisive role in the regulation of the EMT process. Interestingly, upregulated miRNA-15a inhibits the activity of EMT-related genes, such as N-cad, E-cad, and Twist1. In gastric cancer and NSCLC tissues, miRNA-15a was significantly downregulated, while Twist1 gene and its regulated proteins were significantly increased. \[[@B35]\]

Recently, a large number of reports indicate that there is a correlation between the expression of miRNA-15a and the prognosis of various kinds of cancers. To identify the prognostic value of miRNA-15a, we performed this meta-analysis of 10 studies and 1616 patients with 7 cancers. We found that lower expression of miRNA-15a was associated with shorter OS. In other words, patients with higher expression of miRNA-15a have longer OS time than low expression levels. The expression levels of miRNA-15a are downregulated in most cancer types, and they may function as tumor suppressor genes. But obvious heterogeneity was found in our meta-analysis, so we conducted a subgroup analysis by cancer types, race, publication year, and material of miRNA-15a. In the subgroup of cancer types, we found significant heterogeneity in CRC group (*I*^*2*^=70.6,*P*=0.017). When we removed the study of Kontos et al. from the subgroup of colorectal cancer types, no significant heterogeneity was found. In Kontos et al.\'s study, low expression group significantly reduced risk of death, which was contrary to the other three studies, but it was not statistically significant (HR=0.56, 95%CI 0.28-1.14;*P*=0.11). Although there are significant statistical differences in the analysis of DFS (HR=0.19, 95%CI 0.07-0.52; P=0.001), OS is still the best indicator for prognosis in clinical practice. Therefore, we concluded that the main source of heterogeneity is the study by Kontos et al. In addition, we performed survival analysis of human cancers through the Kaplan--Meier plotter database and found that the results of esophageal carcinoma and breast cancer were contrary to our meta-analysis; we analyze the reasons that lead to this result which may have the following aspects: (1) the sample size is too small, for esophageal carcinoma, only 184 cases in the database and 106 cases in the meta-analysis. For breast cancer, comparing 1076 cases in the database, there is only one literature and 230 cases in the meta-analysis. (2) Pathological classification of esophageal cancer is not given in the database, which may also be the cause of inconsistent results. Interestingly, we found in the database that lower expression of miRNA-15a significantly predicted adverse OS in CRC, which is inconsistent with the result of our meta-analysis. However, considering the survival analysis of CRC is still controversial in our meta-analysis, so there should be more clinical studies in the future to discover the relationship between miRNA-15a and the prognosis of CRC. All in all, through our meta-analysis, we found that miRNA-15a may be an important biomarker for predicting the clinical outcome of cancer patients.

To the best of our knowledge, there was no previous meta-analysis of the relationship between miRNA-15a expression levels and the prognosis of cancer patients. Nevertheless, our research has some limitations. Firstly, only 10 studies with 1616 patients were included in our analysis; this may make the result inaccurate, and the reason for the heterogeneity may be because the sample size is too small. Secondly, the design of studies, cut-off value, and measure methods were distinct in different researches, and these factors may have a certain impact on the results of our analysis. Third, we cannot find the HRs and their 95% CIs directly from some literature; thus, we had to estimate results from the Kaplan-Meier curve. This reduced the credibility of our results. Fourth, histopathology is the gold standard for tumor diagnosis, because of its high accuracy. In clinical applications, blood samples were easier to obtain than tissues. Therefore, in the future researches, increasing blood sample applications can provide evidence for clinical diagnosis and treatment in the absence of tissue samples case.

5. Conclusion {#sec5}
=============

As shown in our meta-analysis and bioinformatics, low expression of miRNA-15a may indicate poor OS in cancer patients. But there is no significant association between the expression level and DFS in patient with cancer and there is also controversy in esophageal cancer, breast cancer, and colorectal cancer. Further clinical studies are needed to demonstrate the association between miRNA-15a and cancer prognosis as well as treatment efficiency.
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###### 

The main characteristics of included 10 studies.

  Study            Year   Region      Study design   Disease   N     Stage   Sample        miRNA-15a   Cut-off    Survival analysis   Follow-up Time(month)
  ---------------- ------ ----------- -------------- --------- ----- ------- ------------- ----------- ---------- ------------------- -----------------------
  Utaijaratrasmi   2018   Thailand    R              ICC       72    I-III   Tissue        qRT-PCR     NR         RE                  Median 36
  Gopalan et al    2018   Australia   R              CRC       124   II-IV   Tissue        qRT-PCR     2^−Δct^    SC                  Median 78
  Fesler et al     2018   US          R              CRC       431   II-IV   Tissue        qRT-PCR     0.65       SC                  Up to 120
  Shi et al        2017   China       R              OSM       127   I-III   Tissue        qRT-PCR     2^−ΔΔct^   SC                  Median 47.5
  Kontos et al     2017   Greece      R              CRC       182   I-IV    Tissue        qRT-PCR     0.54       RE                  Median 33
  Li.J et al       2016   China       R              ESCC      106   I-III   Serum         qRT-PCR     2^−ΔΔct^   RE                  Median 28
  Xie et al        2015   China       R              Glioma    128   I-IV    Tissue        qRT-PCR     Median     RE                  Median 42.8
  Shinden et al    2015   Japan       R              BC        230   I-IV    Tissue        qRT-PCR     NR         RE                  Up to 60
  Li.F et al       2015   China       R              MM        90    NR      Bone marrow   qRT-PCR     Median     RE                  Median 15
  Xiao et al       2014   China       R              CRC       126   I-IV    Tissue        qRT-PCR     Median     RE                  Median 74

R, retrospective; BC, breast cancer; ICC, cholangiocarcinoma; CRC, colorectal cancer; OSM, osteosarcoma; ESCC, esophageal squamous cell carcinoma; MM, multiple myeloma; qRT-PCR, quantitative reverse transcription-polymerase chain reaction; RE, reported; SC: survival curve; NR, not reported.

###### 

Summary of HRs and their 95% CI.

  Study            Year   Region      Disease   HR      OS             HR      DFS
  ---------------- ------ ----------- --------- ------- -------------- ------- -------------
  Utaijaratrasmi   2018   Thailand    ICC       3.452   1.188-10.030   NR      NR
  Gopalan et al    2018   Australia   CRC       1.04    0.45-2.38      NR      NR
  Fesler et al     2018   US          CRC       1.57    1.08-2.28      NR      NR
  Shi et al        2017   China       OS        3.281   2.901-3.525    NR      NR
  Kontos et al     2017   Greece      CRC       0.56    0.28-1.14      0.185   0.066-0.518
  Li.J et al       2016   China       ESCC      3.668   1.193-8.283    3.808   1.032-7.838
  Xie et al        2015   China       Glioma    7.52    2.63-21.47     11.56   5.17-25.96
  Shinden et al    2015   Japan       BC        2.56    1.03-7.18      1.42    0.75-2.69
  Li.F et al       2015   China       MM        3.57    1.08-12.50     NR      NR
  Xiao et al       2014   China       CRC       3.016   1.129-6.616    2.782   1.122-6.031

DFS, disease-free survival; HR, hazard ratio; OS, overall survival.

###### 

Quality assessment based on the newcastle--Ottawa scale.

  Study            Year   Selection   Comparability   Outcome   Total score
  ---------------- ------ ----------- --------------- --------- -------------
  Utaijaratrasmi   2018   3           2               3         8
  Gopalan et al    2018   4           2               2         8
  Fesler et al     2018   3           1               2         6
  Shi et al        2017   3           2               2         7
  Kontos et al     2017   3           2               2         7
  Li.J et al       2016   3           2               2         7
  Xie et al        2015   4           2               2         8
  Shinden et al    2015   3           2               2         7
  Li.F et al       2015   3           2               3         8
  Xiao et al       2014   3           2               2         7

###### 

Meta-analysis of overall survival and subgroup analysis.

  Subgroup                No of studies   HR (95% CI)        Model    Heterogeneity   
  ----------------------- --------------- ------------------ -------- --------------- -------
  Race                                                                                 
   Asian                  6               3.10 (2.21-4.34)   random   0               0.640
   European l             4               1.02 (0.53-1.96)   random   69.8            0.037
  Year                                                                                 
   \>2016                 5               1.43 (0.85-2.41)   random   67.9            0.014
   ≦2016                  5               3.67 (2.34-5.74)   random   0               0.642
  Material                                                                             
   Tissue                 8               1.97 (1.22-3.19)   random   70.4            0.001
   Serum/bone marrow      2               3.63 (1.70-7.76)   random   0               0.973
  Cancer type                                                                          
   Colorectal cancer      4               1.27 (0.69-2.36)   random   70.6            0.017
   Other type of cancer   6               3.11 (2.16-4.49)   random   0               0.512

###### 

HRs and 95%CIs of miRNA-15a downregulation in human cancers based on Kaplan-Meier plotter database.

  Cancer types    Sample size   HR (95% CI)         *P*-value
  --------------- ------------- ------------------- -----------
  Human cancers   7385          1.17 (0.95-1.44)    0.150
  BLCA            408           1.49 (1.11-2.00)    0.0081
  BRCA            1076          0.83 (0.58-1.16)    0.27
  CSCC            307           0.55 (0.32-0.93)    0.026
  ESCA            184           0.53 (0.34-0.85)    0.0072
  HNSC            522           1.43 (1.04-1.96)    0.027
  KIRC            516           0.78 (0.55-1.09)    0.14
  KIRP            290           1.59 (0.84-3.03)    0.15
  LIHC            371           1.54 (1.08-2.22)    0.017
  LUAD            504           1.23 (0.92-1.67)    0.16
  LUSC            472           1.69 (1.22-2.38)    0.0014
  OC              485           0.82 (0.65-1.04)    0.10
  PAAD            178           2.22 (1.43-3.45)    0.0002
  PCPG            179           0.14 (0.02-1.20)    0.038
  READ            160           2.63 (1.19-5.88)    0.013
  SARC            259           0.69 (0.46-1.04)    0.075
  STAD            431           1.52 (1.10-2.08)    0.011
  THCA            506           4.17 (0.54-33.33)   0.140
  UCEC            537           1.69 (1.10-2.63)    0.015

BLCA, bladder Carcinoma; BRCA, breast cancer; CSCC, cervical squamous cell carcinoma; ESCA, esophageal carcinoma; HNSC, head-neck squamous cell carcinoma; KIRC, kidney renal clear cell carcinoma; KIRP, kidney renal papillary cell carcinoma; LIHC, liver hepatocellular carcinoma; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; OC, ovarian cancer; PAAD, pancreatic ductal adenocarcinoma; PCPG, pheochromocytoma and paraganglioma; READ, rectum adenocarcinoma; SARC, sarcoma; STAD, stomach adenocarcinoma; THCA, thyroid carcinoma; UCEC, uterine corpus endometrial carcinoma.
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